<DOC>
	<DOCNO>NCT02072863</DOCNO>
	<brief_summary>The purpose Phase 1b study determine maximum tolerate dose ( MTD ) oprozomib combination melphalan prednisone ( OMP ) . The purpose Phase 2 study estimate overall response rate ( ORR ) complete response rate ( CRR ) OMP combination .</brief_summary>
	<brief_title>A Study Oprozomib , Melphalan , Prednisone Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Key 1 . Newly diagnose symptomatic multiple myeloma patient transplant ineligible measureable disease indicate one following : 1 . Serum Mprotein ≥ 500 mg/dL 2 . Urine Mprotein ≥ 200 mg/24 hour 3 . Serum Free Light Chain : Involved free light chain ( FLC ) level ≥ 10 mg/dL , provide serum FLC ratio abnormal 2 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 3 . Creatinine clearance ( CrCl ) ≥ 30 mL/min , either measure calculate use formula Cockcroft Gault [ ( 140 age ) × mass ( kg ) / ( 72 × serum creatinine mg/dL ) ] . Multiply result 0.85 female . Key 1 . Any prior systemic antimyeloma therapy except oral steroid ( dexamethasone total dose 160 mg equivalent within 14 day prior first dose study treatment allow ) . Use topical inhale steroid acceptable . 2 . Congestive heart failure ( New York Hearth Association Class III IV ) , symptomatic ischemia , conduction abnormality uncontrolled conventional intervention , myocardial infarction within 6 month prior first dose 3 . Known suspected HIV , active Hepatitis A , B C virus infection ( Exception : Subjects chronic clear HBV HCV infection stable liver function test [ bilirubin , AST ] allow ) . 4 . Significant neuropathy ( Grade 2 pain high ) time first dose . 5 . Plasma cell leukemia . 6 . POEMS syndrome ( polyneuropathy , organomegaly , endocrinopathy , monoclonal protein , skin change ) 7 . Known amyloidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>